红日药业(300026.SZ)发布上半年业绩，归母净利润7863万元，下降46.95%

Core Viewpoint - Hongri Pharmaceutical (300026.SZ) reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first half of 2025 was 2.795 billion yuan, a year-on-year decrease of 6.72% [1] - The net profit attributable to shareholders of the listed company was 78.63 million yuan, reflecting a year-on-year decrease of 46.95% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 69.18 million yuan, down 49.53% year-on-year [1] - Basic earnings per share were reported at 0.03 yuan [1]